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Abstract
Fas-associated protein with death domain (FADD) was first identified for its role in linking death
receptors to the apoptotic signaling pathway with subsequent cell death. Later studies reported
non-apoptotic functions for FADD in normal cells and cancer cells. Non-apoptotic functions for
FADD in osteosarcoma (OS) have not been reported. In this study, FADD protein expression was
knocked down in human CCHOSD, LM7, and SaOS2 OS cell lines followed by assessment of
sensitivity to TNFα- or TRAIL-induced cell death. Knock down of FADD significantly increased
TNFα-induced cell death in LM7 and SaOS2 cell lines. The mode of TNFα-induced cell death was
apoptosis and not necroptosis. Inhibition of nuclear factor kappa B (NFκB) in wildtype cells
increased TNFα-induced cell death to similar levels observed in FADD knockdown cells, suggesting
a role for FADD in NFκB pro-survival cell signaling. In addition, knock down of FADD increased
SMAC mimetic-mediated TNFα-induced cell death in all cell lines studied. The results of this study
indicate that FADD has a pro-survival function in OS following TNFα treatment that involves NFκB
signaling. The results also indicate that the pro-survival function of FADD is associated with XIAP
activity.
Key words: FADD, osteosarcoma, TNFα, NFκB, XIAP

Introduction
Osteosarcoma (OS) is the most common type of
bone cancer found in children and teens [1]. The
long-term survival rate for localized OS is
approximately 65 percent [2] while the long-term
survival rate for OS that has spread to other parts of
the body is less than 30 percent [3]. These long-term
survival rates underscore the need for better
therapeutic options for OS. Development of improved
therapies for OS requires a better understanding of
the pro-survival and pro-death signaling pathways
within OS.

Fas-associated protein with death domain
(FADD) was discovered as an adaptor protein that
interacts with the intracellular death domain (DD) of
the Fas receptor (Fas) following ligation of Fas with
Fas ligand (FasL) with subsequent apoptosis [4].
Studies later identified additional FADD interacting
proteins.
For
example,
upon
TNF-related
apoptosis-inducing ligand (TRAIL) receptor ligation,
FADD binds the intracellular DD of the TRAIL
receptor [5]. Additionally, upon TNF receptor-1
(TNFR1) ligation with TNFα, FADD binds
TNFR-associated death domain (TRADD) protein [6].
http://www.jcancer.org
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Following interaction of FADD with Fas, TRAIL
receptor or TRADD, FADD recruits procaspase-8 via
its death-effector-domain (DED) with subsequent
activation of the extrinsic apoptotic pathway.
Subsequent studies on FADD revealed
non-apoptotic functions for FADD. For example,
FADD has been reported to promote cell proliferation
and cell cycle regulation in T cells [7, 8]. These reports
were among the first to show that FADD has
non-apoptotic functions. Later studies reported that
FADD has non-apoptotic functions beyond T cells.
For example, FADD has been reported to protect
pancreatic cancer cells from anticancer drug-induced
cell death [9].
The tumor necrosis factor super family (TNFSF)
of ligands is a diverse group of cytokines that induce a
variety of responses from inflammation to apoptosis.
TNFSF ligands include TNFα, TRAIL and FasL. These
ligands are also referred to as death ligands and their
cognate receptors are referred to as death receptors.
TNFα is the most pleiotropic member of the TNFSF
ligand family. TNFα is a pro-inflammatory cytokine
secreted by multiple immune cells. TNFα promotes
cancer cell growth, angiogenesis, metastasis and
apoptosis [10].
The NFκB family of proteins consist of five
members: p105/50, p110/52, RelB, RelA(p65) and
c-Rel. Active NFκB transcription factor exist as a
homodimer
or
heterodimer,
with
p50/p65
representing the prominent dimer. Upon activation of
the NFκB pathway, the NFκB inhibitor, inhibitor of
NFκB (IκB), is phosphorylated by IκB kinase (IKK)
causing the release of NFκB and translocation to the
nucleus where NFκB serves as a transcription factor.
NFκB is primarily associated with expression of
pro-survival genes such as Bcl-2 [11], c-flip [12], and
XIAP [13].
X-linked inhibitor of apoptosis (XIAP) is a target
gene of NFκB that promotes cell survival following
certain cell death-inducing stimuli. XIAP inhibits
apoptosis by binding to activated caspases-3, -7 and -9
[14]. Therefore, XIAP is a negative regulator of
apoptosis. Endogenous inhibition of XIAP is achieved
by second mitochondrial-derived activator of
caspases (SMAC). SMAC binds XIAP, thus preventing
XIAP-mediated inhibition of apoptosis. The ability of
SMAC to inhibit XIAP was the basis for the
investigation of SMAC mimetics as a therapeutic
option for cancer [15].
The role of FADD in death ligand signaling and
death ligand-induced cell death in OS has not been
well characterized. Here, we report that knock down
of FADD sensitizes OS to TNFα-induced cell death.
We also report that inhibition of NFκB increases
TNFα-induced cell death. In addition, we report that
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inhibition of XIAP increases TNFα-induced cell death
in FADD knockdown cells. The results of this study
indicate that FADD has a pro-survival role in OS
following TNFα treatment that involves NFκB
activation and XIAP activity.

Materials and Methods
Antibodies and Reagents
TNFα and TRAIL cytokines were purchased
from Peprotech (Rocky Hill, NJ). Antibodies against
cleaved caspase-3, phospho-inhibitor of NFκB (pIκB),
p50, p65, Lamin B and FADD were purchased from
Cell Signaling Technology, Inc. (Danvers, MA).
Pan-caspase inhibitor (Z-VAD-FMK) was purchased
from Enzo Life Sciences (New York, NY). Ripa lysis
buffer was purchased from Santa Cruz Biotechnology,
Inc. (Dallas, TX). Necrostatin-1, PS-1145 and actin
antibody were purchased from Sigma Aldrich (St.
Louis, MO). SM-164 was purchased from ApexBIO
(Houston, TX). Fetal bovine serum (FBS) was
purchased from Atlanta Biologicals (Lawrenceville,
GA). Dulbecco’s modified eagle medium (DMEM) cell
culture medium and cell culture supplements were
purchased from Invitrogen (Carlsbad, CA).

Cell Lines and Cell Culture
CCHOSD, LM7 and SaOS2 are human OS cell
lines. CCHOSD is a human metastatic osteosarcoma
cell line. LM7 is the human high metastatic [16]
subline of the low metastatic potential SaOS2 cell line
[17]. Prior to experimentation, cells were
fingerprinted by short tandem repeat analysis of DNA
by the Characterized Cell Line Core Facility at The
U.T. MD Anderson Cancer Center. Cells were tested
for mycoplasma contamination using Lonza
mycoplamsa detection kit (Saint Beauzire, France).
Cells were cultured in DMEM containing 10% FBS
and supplemented with antibiotic, non-essential
amino acid solution, MEM vitamin mixture, and
cultured in an incubator maintained at 5% CO2 and
37oC.

Generation of FADD knockdown cells
Lentiviral shRNA (GE Dharmacon, Lafayette,
CO) targeted to FADD RNA was used to knock down
FADD protein expression. Lentivirus was generated
by transfecting 293T cells with 7ug/ml transfer
plasmid (shRNA plasmid), 5ug/ml psPAX2
(packaging plasmid) and 4ug/ml pMD2.G (envelope
plasmid). Forty-eight hours after 293T cell
transfection, supernatant containing lentivirus was
collected and immediately used for infection or stored
at -80oC. For infection, 2 ml of supernatant containing
lentivirus were added to each well of a 6-well plate
containing 2x105 cells. Cells were incubated with
http://www.jcancer.org
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lentivirus for 8 h. Efficiency of FADD protein knock
down was determined 72 h following infection by
assessing FADD protein levels via western blot
analysis. Two FADD knockdown cell lines were
generated using two different lentiviral shRNA
sequences [TRCN0000040268, TRCN0000040269].
Cells infected with empty shRNA vector (no
shRNA-specific insert) are hereafter referred to as
wildtype (wt). Cells infected with shRNA targeted
against FADD RNA are hereafter referred to as FADD
knockdown (fkd).

Cell Viability
To determine cell viability, 1x105 cells/well were
seeded in 12-well plates and treated with drug 24 h
later as indicated in figure legends. Following drug
treatment, floating cells and attached cells were
collected followed by cell viability determination. Cell
viability was determined by trypan blue exclusion
assay using an automated cell counter (Vi-Cell,
Beckman Coulter, Miami, FL). Cells restricting trypan
blue entry were considered viable.

Western blot
Following drug treatment, floating cells and
attached cells were collected and centrifuged at 1000
rpm for 5 min at 4oC. The resultant pellet was lysed
with RIPA lysis buffer containing protease and
phosphatase inhibitor cocktail and centrifuged at
12,000 rpm for 10 min at 4oC. Supernatants were then
collected and total protein was determined by BioRad
reagent (BioRad Laboratories, Hercules, CA). Where
applicable, cytoplasmic and nuclear fractions were
separated by use of a nuclear extraction kit according
to manufacturer’s instructions (Cayman Chemical,
Ann Arbor, MI). Fifty micrograms of protein were
resolved in SDS-polyacrylamide gels (SDS-PAGE)
and transferred onto nitrocellulose membranes
(BioRad Laboratories, Hercules, CA). Membranes
were next blocked with 5% nonfat milk followed by
incubation with antibodies against FADD, cleaved
caspase-3, pIκB, p50, p65, Lamin B or beta-actin.
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Membranes were next washed and incubated with
appropriate secondary antibody conjugated to HRP
(GE Healthcare Life Sciences, Piscataway, NJ).
Following
secondary
antibody
incubation,
membranes were washed and signal detected with
ECL detection reagent (GE Healthcare Life Sciences,
Piscataway, NJ). Lamin B served as a nuclear marker.
Beta-actin served as a protein loading control.

TNFα receptor expression
Cells were grown to approximately 70%
confluency followed by removal with trypsin and
washed twice with PBS. Cells were next treated with
PE-conjugated TNFR1 antibody or PE-conjugated IgG
control antibody. Following antibody treatment, cells
were washed twice and surface TNFR1 expression
analyzed by flow cytometry.

Statistical Analysis
Results are presented as means + standard error
mean (SEM). Experimental data were analyzed using
2-tailed Student t test. P-values <0.05 were considered
statistically significant and is indicated by an asterisk.

Results
Knock down of FADD protein increases
sensitivity to TNFα
Following confirmation of FADD knockdown
(Figure 1), cells were treated with TNFα or TRAIL.
Cell death in TNFα-treated wildtype CCHOSD
(CCHOSDwt) or FADD knockdown CCHOSD
(CCHOSDfkd) cells was unchanged (Figure 2A).
TNFα treatment induced significant cell death in
FADD knockdown LM7 (LM7fkd) and FADD
knockdown SaOS2 (SaOS2fkd) cells (Figure 2B-C).
TRAIL treatment induced significant cell death in
LM7fkd cells (Figure 2B). To determine if FADD
knockdown affected TNFα receptor (TNFR1)
expression, TNFR1 expression was assessed. Knock
down of FADD did not alter surface expression of
TNFR1 (Figure 3).

Figure 1. Lentiviral shRNA directed against FADD effectively knocks down FADD protein expression. Cells were infected with shRNA lentivirus targeted against
FADD RNA. Following infection, FADD protein levels were determined by western blot analysis. Beta-actin served as a protein loading control.

http://www.jcancer.org
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Figure 2. Knock down of FADD increases TNFα-induced cell death. Cells were treated with 100ng/ml TNFα or 100ng/ml TRAIL for 24 h. Following death ligand
treatment, cell viability was determined by trypan blue exclusion assay. A, CCHOSD. B, LM7. C, SaOS2. Data represents the results of at least three independent experiments,
+ SEM. *, p<0.05 was considered significant.

Caspase inhibition, but not necroptosis
inhibition, reverses TNFα-induced cell death
The mode of cell death responsible for
TNFα-induced cell death in LM7fkd cells where TNFα
induced the most significant cell death was
investigated. TNFα has been reported to cause
necroptosis [18]. Therefore, necroptosis was initially
investigated as the mode of TNFα-induced cell death.
LM7wt and LM7fkd cells were pretreated with the
necroptosis inhibitor, necrostatin-1, followed by
TNFα treatment. Pretreatment with necrostatin-1 did

not rescue LM7fkd cells from TNFα-induced cell
death (Figure 4A), suggesting that necroptosis was
not the mode of cell death for TNFα-induced cell
death in LM7fkd cells. However, pretreatment of
LM7fkd cells with a pan-caspase inhibitor
(Z-VAD-FMK) followed by TNFα treatment reversed
TNFα-induced cell death, suggesting apoptotic cell
death (Figure 4B). Pan-caspase inhibitor effectively
blocked
TNFα-induced
caspase-3
activation.
Caspase-3 activation was observed in both LM7wt
and LM7fkd cells following TNFα treatment (4C).

http://www.jcancer.org
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Figure 3. TNFα receptor surface expression. Untreated wildtype and FADD knockdown cells were incubated with PE-labeled TNFR1 antibody. TNFα receptor surface
expression was analyzed by flow cytometry. Filled histogram plot: IgG control. Unfilled histogram plot: TNFR1 expression.

Figure 4. Inhibition of caspases, but not necroptosis, reverses TNFα-induced cell death. A, Inhibition of necroptosis does not reverse TNFα-induced cell death.
Cells were pretreated with 20uM necrostatin-1 for 2 h followed by 100ng/ml TNFα treatment for 24 h. B, Inhibition of caspases reverses TNFα-induced cell death. Cells were
pretreated with 30uM pan-caspase inhibitor for 2 h followed by 100ng/ml TNFα treatment for 24 h. Cell viability was determined by trypan blue exclusion assay. Data represents
the results of at least three independent experiments, + SEM. *, p< 0.05 was considered significant. C, TNFα treatment causes caspase-3 activation in LM7wt and LM7fkd cells.
Pan-caspase inhibitor pretreatment blocks TNFα-induced caspase-3 activation. Immunoblot is representative of immunoblots from three independent experiments.

http://www.jcancer.org
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Figure 5. Functional status of NFκB signaling. A, IkB phosphorylation following TNFα treatment. Cells were treated with 100ng/ml TNFα for times indicated in figure.
Following TNFα treatment, cells were collected, lysed and total protein probed for pIkB. Beta-actin served as a loading control. Immunoblot is representative of immunoblots
from three independent experiments. B, Translocation of p50 and p65 to the nucleus following TNFα treatment. Cells were treated with 100ng/ml TNFα for 60 min. Following
TNFα treatment, cells were collected and nuclear and cytoplasmic fractions separated. Lamin B served as the nuclear marker. Immunoblot is representative of immunoblots from
two independent experiments. C, PS-1145 blocks phosphorylation of IkB. Cells were pretreated with 20uM PS-1145 for 2 h followed by treatment with 100ng/ml TNFα for 60
min. Following TNFα treatment, cells were collected, lysed and total protein probed for pIkB. Beta-actin served as a protein loading control. Immunoblot is representative of
immunoblots from three independent experiments.

Inhibition of NFκB activation increases
TNFα-induced cell death

Inhibition of XIAP increases TNFα-induced
cell death in FADD knockdown cells

TNFα treatment induced phosphorylation of IkB
in both LM7wt and LM7fkd cells (Figure 5A). NFκB
activation and functional status of the NFκB signaling
pathway was confirmed by the translocation of p50
and p65 to the nucleus following TNFα treatment
(Figure 5B). PS-1145 inhibits IKK, thus preventing
NFκB activation. Pretreatment with PS-1145 reversed
TNFα-induced IkB phosphorylation (Figure 5C),
suggesting inhibition of NFκB. Therefore, to
investigate the effect of NFκB inhibition on TNFα
treatment, wildtype and FADD knockdown OS cells
were pretreated with PS-1145 followed by TNFα
treatment. Pretreatment with PS-1145 significantly
increased TNFα-induced cell death in LM7wt cells to
similar levels observed in LM7fkd cells treated with
TNFα alone (Figure 6B), suggesting that the
TNFα-induced cell death observed in LM7fkd cells
was associated with NFκB activation. Inhibition of
NFκB also increased TNFα-induced cell death in
SaOS2fkd cells to similar levels observed in LM7fkd
cells treated with TNFα alone (Figure 6C).

To investigate the effect of XIAP inhibition on
TNFα treatment in FADD knockdown cells, wildtype
and FADD knockdown OS cells were pretreated with
the XIAP inhibitor, SM-164, followed by TNFα
treatment. FADD knockdown increased SM-164mediated TNFα-induced cell death in all OS cell lines
investigated (Figure 7A-C).

Discussion
FADD was first identified as an adaptor protein
that links Fas to caspase-8 with subsequent activation
of apoptosis and subsequent cell death. Subsequent
studies reported non-apoptotic functions for FADD.
The early non-apoptotic functions for FADD were
reported in T cells [7, 8]. Later studies reported
non-apoptotic or pro-survival functions for FADD
beyond T cells, to include cancer cells [9]. While
FADD has recently been reported to have a protective
role against anticancer drug-induced cell death in
pancreatic cancer cells [9], there are no reports on the
effect of FADD knockdown on cell death in OS
http://www.jcancer.org
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induced by death ligands such as TNFα or TRAIL.
This study set out to investigate the effect of TNFα on
cell death in OS cells with FADD knockdown. The
death ligand TRAIL was also investigated as a
comparison death ligand.
In the present study, knock down of FADD in
LM7 or SaOS2 cells caused significant cell death
following TNFα treatment. The initially reported role
of FADD in death receptor-initiated apoptosis
suggests that knock down of FADD should inhibit
death
ligand-induced
apoptosis.
Therefore,
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considering the report that TNFα triggers necroptosis
in cells with an inhibited apoptotic pathway [19, 20],
necroptosis was investigated as the mode of
TNFα-induced cell death in LM7fkd cells following
TNFα treatment. Necroptosis is a form of cell death
referred to as programmed necrosis and TNFα is the
principal inducer of necroptosis [21]. LM7wt and
LM7fkd cells were pretreated with the necroptosis
inhibitor, necrostatin-1, followed by TNFα treatment.
Necrostatin-1 pretreatment did not reverse
TNFα-induced cell death (Figure 4A), suggesting

Figure 6. Inhibition of IκB kinase (IKK) increases TNFα-induced cell death. Cells were pretreated with the IKK inhibitor, PS-1145, for 2 h followed by treatment with
100ng/ml TNFα for 24 h. Cell viability was determined by trypan blue exclusion assay. A, CCHOSD, B, LM7, C, SaOS2. Data represents the results of at least three independent
experiments, + SEM. *, p< 0.05 was considered significant.

http://www.jcancer.org
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another mode of cell death. Apoptosis was next
investigated as the mode of cell death by pretreating
cells with a pan-caspase inhibitor followed by TNFα
treatment. Pan-caspase inhibition reversed the
TNFα-induced cell death in LM7fkd cells, indicating
caspase-mediated cell death, or apoptosis, as the
mode of TNFα-induced cell death (Figure 4B). To
further confirm apoptosis, LM7wt and LM7fkd cells
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were probed for activated caspase-3 following TNFα
treatment. Considering the insignificant cell death
observed in LM7wt cells following TNFα treatment,
we expected that activation of caspase-3 would be
restricted to TNFα-treated LM7fkd cells. As expected,
activated caspase-3 was detected in LM7fkd cells.
Surprisingly, an appreciable level of activated
caspase-3 was observed in LM7wt cells (Figure 4C).

Figure 7. Knock down of FADD increases TNFα-induced cell death in XIAP-inhibited cells. Cells were pretreated with SM-164 for 2 h followed by treatment with
100ng/ml TNFα. Cell viability was determined by trypan blue exclusion assay. A, CCHOSD, B, LM7, C, SaOS2. Data represents the results of at least three independent
experiments, + SEM. *, p< 0.05 was considered significant.

http://www.jcancer.org
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Considering the observation in the present study
that FADD knockdown increases TNFα-induced cell
death and the report that TNFα activates the NFκB
pathway [22], the effect of NFκB inhibition in FADD
knockdown OS cells was investigated. NFκB was
inhibited in wildtype and FADD knockdown OS cells
followed by TNFα treatment. Inhibition of NFκB
significantly increased TNFα-induced cell death in
LM7wt and SaOS2wt cells indicating that NFκB has a
protective role in LM7 and SaOS2 cells following
TNFα treatment. Interestingly, inhibition of NFκB in
FADD knockdown cells increased TNFα-induced cell
death beyond that observed in NFκB-inhibited
wildtype cells (Figures 6B-C). These observations
suggest that FADD affects NFκB activation and
signaling. Indeed, FADD has previously been
reported to affect NFκB activation. For example,
FADD has been linked to NFκB activation in Jurkat
cells [23, 24] and over expression of FADD in human
293 cells induce NFκB activation [25]. Negative
regulation of NFκB activation by FADD has also been
reported in TNFα-treated cardiomyocytes [26] and
FADD
suppresses
lipopolysaccharideand
IL-1β-induced activation of NFκB in endothelial cells
[27]. Still, these studies did not investigate the effect of
FADD knockdown on NFκB signaling following
TNFα treatment.
At the time of publication, only one study was
found that reported a link between FADD modulation
and sensitivity to TNFα. Khwaja and colleagues
reported that inhibition of the FADD/caspase
signaling pathway sensitizes leukemia cells to
TNFα-induced cell death [28]. In the present study,
caspase inhibition reversed TNFα-induced cell death
in FADD knockdown cells. This opposing observation
may be attributed to two factors. First, the cell lines
used in the present study differ from the cell lines
used in the study carried out by Khwaja and
colleagues [28]. Second, in the present study, FADD
protein
expression
was
reduced
by
lentiviral-mediated knock down of FADD, while a
dominant negative FADD lacking a DED was used in
the study carried out by Khwaja and colleagues [28].
Inhibition of XIAP increases TNFα-induced cell
death in melanoma [29] and OS [30]. This observation
is also reported in the current study, indicating a role
for XIAP in protection against TNFα-induced cell
death in the OS cell lines investigated in this study.
XIAP inhibits apoptosis by binding to and inhibiting
activated caspases-3, -7 and -9 [14]. Therefore,
following the observation of activated caspase-3 in
both LM7wt and LM7fkd cells with significant cell
death restricted to LM7fkd cells, we suspected that the
NFκB target gene, XIAP, may be involved. It is
plausible that although caspase-3 was activated in
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LM7wt cells, XIAP inhibited caspase-3 from
facilitating apoptotic-induced cell death. This would
suggest that FADD knockdown inhibits XIAP activity,
thus allowing TNFα-induced apoptosis in LM7fkd
cells. To investigate the role of XIAP in TNFα-induced
cell death in FADD knockdown OS cells, wildtype
and FADD knockdown OS cells were pretreated with
the XIAP inhibitor, SM-164, followed by treatment
with TNFα. While inhibition of XIAP induced
TNFα-induced cell death in all wildtype OS cells
investigated, the amount of cell death was greater in
XIAP-inhibited FADD knockdown OS cells following
TNFα treatment (Figure 7A-C). This observation
further supports a pro-survival role for FADD
following TNFα treatment in OS.
The observation that FADD knockdown
increased TNFα-induced cell death in both
NFκB-inhibited and XIAP-inhibited cells suggest that
FADD has a role in linking TNFα signaling to
NFκB-mediated pro-survival pathways. It is plausible
that in certain contexts or cancer cells, FADD may
serve as an adaptor protein that links TNFα signaling
to the pro-survival NFκB pathway. Therefore, when
FADD is inhibited by mutation or there is decreased
expression of FADD, the effect of TNFα signaling is
cell death. In the absence of FADD, the c-Jun
N-terminal kinase (JNK) pathway has been suggested
as a pathway for TNFα-induced apoptosis [31].
Therefore, although not investigated in the current
study, it is plausible that the cell death observed in
FADD knockdown cells may occur through the JNK
pathway.
Cellular status of FADD has been proposed to
have clinical relevance as a prognostic indicator for
certain
cancers.
For
example,
increased
phosphorylation of FADD has been implicated in
poor prognosis in lung adenocarcinoma [32].
Additional observations supporting the pro-survival
role of phosphorylated FADD in cancer is the report
that inhibition of FADD phosphorylation increases
cisplatin-induced cell death in A549 lung cancer cells
[33] and the report of increased FADD
phosphorylation in T cell lymphomas [34].
Furthermore, FADD gene amplification and FADD
overexpression has been reported in oral squamous
cell carcinoma [35].
Although non-apoptotic functions of FADD
were first reported more than 15 years ago, reports of
non-apoptotic functions of FADD in cancer is limited
and there are no reports on the non-apoptotic
functions of FADD in OS. The observation in the
present study that FADD knockdown increases
TNFα-induced cell death coupled with the
observation that inhibition of NFκB in LM7wt cells
increases TNFα-induced cell death to similar levels
http://www.jcancer.org
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observed in LM7fkd cells supports a regulatory role
for FADD in NFκB pro-survival signaling in OS.

Conclusions
In conclusion, the results of this study reveal a
pro-survival function for FADD in OS following
TNFα treatment that involves NFκB activation. In
addition, the results suggest that FADD is involved in
XIAP-mediated protection following TNFα treatment.
We base this conclusion on the observation that knock
down of FADD increased TNFα-induced cell death
(Figure 2B). In addition, inhibition of NFκB resulted in
TNFα-induced cell death in LM7wt cells that was
similar to that observed in LM7fkd cells (Figure 6B).
Furthermore, FADD knockdown increased SMAC
mimetic-mediated TNFα-induced cell death (Figure
7A-C). To the best of our knowledge, this is the first
report of a pro-survival function for FADD in OS
following TNFα treatment. The report presented here
of a pro-survival function for FADD in OS and other
studies that report pro-survival functions of FADD in
other cancers underscore the need to further
investigate the multifunctional role of FADD in cancer
initiation, progression and survival.
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